Key Highlights
- Shares of Xenon Pharmaceuticals soared 40% following positive Phase 3 X-TOLE2 data showing azetukalner achieved its primary goal across both dosing cohorts.
- The higher 25 mg dosing regimen delivered a 53.2% median reduction in monthly focal onset seizure episodes versus baseline, compared to 10.4% for placebo recipients.
- These findings surpassed the previous Phase 2b X-TOLE trial, which demonstrated a 34.6% placebo-adjusted median percent reduction.
- More than half of participants receiving 25 mg (54.8%) experienced at least a 50% decrease in seizure occurrence.
- The company intends to submit a New Drug Application (NDA) to the FDA during the third quarter of 2026.
Shares of Xenon Pharmaceuticals (XENE) climbed 40% during Monday’s trading session after the biotechnology firm revealed that its Phase 3 X-TOLE2 clinical trial of azetukalner successfully achieved its primary objective in treating focal onset seizures. The better-than-anticipated outcomes triggered a substantial rally in the stock price at market open.
Xenon Pharmaceuticals Inc., XENE
The clinical study recruited 380 adult patients suffering from highly refractory epilepsy. These individuals had previously attempted a median of five different antiseizure therapies and continued to experience approximately 12.75 seizures monthly at the study’s commencement.
Patients receiving the 25 mg dose of azetukalner demonstrated a median reduction of -53.2% in monthly focal onset seizure frequency compared to their baseline measurements. Meanwhile, the placebo cohort experienced only a -10.4% reduction. This translates to a placebo-adjusted treatment effect of -42.7%.
This outcome carries significant weight. The preceding Phase 2b X-TOLE trial had demonstrated a placebo-adjusted median reduction of -34.6% for the 25 mg cohort. The X-TOLE2 results substantially exceeded this benchmark.
The lower 15 mg dose also delivered positive outcomes, achieving a -34.5% median reduction versus placebo, although the 25 mg data attracted the greatest interest from investors and analysts.
Additional Efficacy Measures Achieved
The study successfully met its crucial secondary efficacy measure as well. Among participants taking 25 mg, 54.8% experienced at least a 50% reduction in monthly seizure frequency — a metric referred to as the 50% Responder Rate. This contrasted with merely 20.8% in the placebo arm. The 15 mg cohort achieved a 37.6% responder rate.
Out of 332 study participants who finished the double-blind treatment phase, 322 enrolled in the ongoing open-label extension trial.
The drug’s safety characteristics remained acceptable. The most frequently reported adverse reactions included dizziness, headache, somnolence, and fatigue. Discontinuation rates due to treatment-related adverse events were 14.5% for the 25 mg cohort, 4.8% for the 15 mg cohort, and 3.2% for those receiving placebo.
Ian Mortimer, CEO of Xenon, stated the findings demonstrated “the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study,” according to the company’s official announcement.
Regulatory Timeline and Market Outlook
Xenon intends to file an NDA with the FDA seeking approval for azetukalner in focal onset seizures during the third quarter of 2026. Upon approval, this would represent the first KV7 potassium channel opener commercially available for epilepsy treatment.
Analysts at Stifel suggested the robust trial results may prompt market watchers to increase their peak sales forecasts and market penetration projections for the medication.
Azetukalner offers several practical benefits compared to currently available treatments — including once-daily administration, no dose titration requirements, and minimal drug-drug interaction concerns.
The complete X-TOLE2 dataset will be shared during an oral presentation at the American Academy of Neurology (AAN) Annual Meeting scheduled for April.
Xenon is simultaneously advancing azetukalner development for major depressive disorder, though that clinical program was not addressed in Monday’s announcement.
The stock price climbed approximately 40% during Monday morning trading, with the substantial movement attributed exclusively to the Phase 3 clinical data release.
